An Open-label, Single-arm Study to Evaluate the Pharmacokinetics and Safety of Subcutaneous Sonelokimab in Adolescents Aged ≥12 to ≤17 Years At the Time of Study Inclusion with Active Moderate to Severe Hidradenitis Suppurativa
Latest Information Update: 30 Jun 2026
At a glance
- Drugs Sonelokimab (Primary)
- Indications Hidradenitis suppurativa
- Focus Adverse reactions; Pharmacokinetics; Registrational
- Acronyms VELA-TEEN
- Sponsors MoonLake Immunotherapeutics
Most Recent Events
- 22 Jun 2026 According to a MoonLake Immunotherapeutic media release, the company will hold an Investor Day for investors and analysts on June 22, 2026 to present data from this trial
- 22 Jun 2026 Results published in the MoonLake Immunotherapeutic Media Release
- 06 May 2026 Planned End Date changed from 27 Mar 2026 to 28 Sep 2026.